DC101-CP132单克隆抗体是原始DC101单克隆的重组嵌合型抗体。可变结构域序列与原始DC101相同，但是恒定区序列已经从大鼠IgG1变为小鼠IgG2a。DC101-CP132单克隆抗体像原始大鼠IgG1抗体一样，不包含Fc突变。
DC101-CP132单克隆抗体能与小鼠VEGFR-2(血管内皮生长因子受体2)反应，VEGFR-2也称为CD309、KDR和Flk-1。VEGFR-2是酪氨酸蛋白激酶家族的成员。当结合到其配体血管内皮生长因子时发挥生理作用，血管内皮生长因子受体-2在血管发育和通透性中起关键作用。血管内皮生长因子受体-2在成人心脏、肺、肾、脑和骨骼肌的内皮细胞中高表达，在其他组织中低表达。DC101单克隆抗体已被证明在体内抑制VEGFR-2信号传导。
产品详情：
| 产品名称 | RecombiMAb anti-mouse VEGFR-2 / 欣博盛生物 |
| 产品货号 | CP132 |
| 产品规格 | 1/5/25/50/100mg |
| 反应种属 | Mouse |
| 克隆号 | DC101-CP132 |
| 同种型 | Mouse IgG2a(switched from rat IgG1) |
| 免疫原 | Mouse VEGFR-2-SEAPs soluble receptor |
| 实验应用 | in vivo blocking of VEGF/VEGFR-2 signaling* |
| 产品形式 | PBS, pH 7.0,Contains no stabilizers or preservatives |
| 纯度 | >95%, Determined by SDS-PAGE |
| 聚合 | <5%, Determined by SEC |
| 无菌处理 | 0.2 µm filtration |
| 纯化方式 | Protein G |
| 分子量 | 150 kDa |
| 小鼠病原检测 | Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative |
| 保存条件 | 抗体原液保存在4°C，不能冷冻保存。 |
| 推荐同型对照 | InVivoPlus mouse IgG2a isotype control, unknown specificity（货号BP0085） |
| 推荐抗体稀释液 | InVivoPure pH 7.0 Dilution Buffer（货号IP0070） |
该产品自上市已被多篇SCI文献引用，品质有保证，以下是部分已发表的文献引用：
| 应用 | 文章 |
| 体内VEGF/VEGFR-2 信号阻断 (in vivo blocking of VEGF/VEGFR-2 signaling) | 1. Ding, X., et al. (2015). 'Distinct functions of epidermal and myeloid-derived VEGF-A in skin tumorigenesis mediated by HPV8' Cancer Res 75(2): 330-343. 2. Lee, H. J., et al. (2015). 'Inhibition of vascular endothelial growth factor A and hypoxia-inducible factor 1alpha maximizes the effects of radiation in sarcoma mouse models through destruction of tumor vasculature' Int J Radiat Oncol Biol Phys 91(3): 621-630. 3. Arulanandam, R., et al. (2015). 'VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection' Cancer Cell 28(2): 210-224. 4. Kizhatil, K., et al. (2014). 'Schlemm’s canal is a unique vessel with a combination of blood vascular and lymphatic phenotypes that forms by a novel developmental process' PLoS Biol 12(7): e1001912. |
| 体内VEGF/VEGFR-2信号阻断， 体外VEGFR信号阻断 (in vivo blocking of VEGF/VEGFR-2 signaling, in vitro blocking of VEGFR signaling) | 1.Larrayoz, M., et al. (2014). 'Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype' EMBO Mol Med 6(4): 539-550. |
